- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, IO biomarker: Mechanism of Action Study for Psoriasis (clinicaltrials.gov) - Jul 19, 2012 P4, N=33, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / AbbVie
Enrollment open: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Jun 28, 2012 P4, N=100, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Adalimumab for Inflammatory Osteoarthritis (clinicaltrials.gov) - Jun 11, 2012 P1/2, N=20, Completed, Initiation date: Mar 2012 --> Jul 2012 Active, not recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Surgery: FACC: Anal Crohn Fistula Surgery (clinicaltrials.gov) - Jun 5, 2012 P=N/A, N=180, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Pneumococcal vaccines: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease (clinicaltrials.gov) - Jan 5, 2012 P4, N=172, Recruiting,
|